[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR081758A1 - Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas - Google Patents

Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas

Info

Publication number
AR081758A1
AR081758A1 ARP110101141A ARP110101141A AR081758A1 AR 081758 A1 AR081758 A1 AR 081758A1 AR P110101141 A ARP110101141 A AR P110101141A AR P110101141 A ARP110101141 A AR P110101141A AR 081758 A1 AR081758 A1 AR 081758A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
formula
alkyl
heterocyclic group
Prior art date
Application number
ARP110101141A
Other languages
English (en)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of AR081758A1 publication Critical patent/AR081758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula [1] en donde X es -N=, -CH=, -C(-R5)=, -C(-Br)=, o -C(-Cl)=; R5 es alquilo inferior o halo(inferior)alquilo; W es -CH2-, -S-, o -O-; cuando W es -CH2-, U es -CH2-, -S-, u -O-, y cuando W es -S- u -O-, U es -CH2-; R1 y R2 cada uno es, independientemente, hidrógeno, halógeno, hidroxilo, carboxi, alquilo inferior opcionalmente sustituido, grupo carbocíclico opcionalmente sustituido, o un grupo heterocíclico opcionalmente sustituido; o R1 y R2 en forma conjunta con un átomo cercano pueden formar un grupo carbocíclico opcionalmente sustituido, o un grupo heterocíclico opcionalmente sustituido; R3 es H, -OCH3, o -NH-CH(=O); R4 cada uno es independientemente, hidrógeno, halógeno, hidroxilo, -CN, -C(=O)-R6, -C(=O)-OH, alquilo inferior, halo(inferior)alquilo o -OR6; k es un entero de 0 a 2; R6 es alquilo inferior o halo(inferior)alquilo; m es un entero de 0 a 2; Q es un enlace, grupo carbocíclico opcionalmente sustituido, o un grupo heterocíclico opcionalmente sustituido; G es i) -C(=O)- o ii) un grupo heterocíclico de 5 miembros; cuando G es -C(=O)-, a) D es un enlace simple, -NH-, o -R7-NH-, R7 es un alquileno inferior; y E un grupo cíclico opcionalmente sustituido seleccionado de las fórmulas (1) a (45); o b) D es un grupo de la fórmula [2] ó [3] en donde, q es 0 ó 1; y E es un grupo de la fórmula (46); y ii) cuando G es un grupo heterocíclico de 5 miembros; D es -CH2- o -CH2-CH2-; y E es un grupo de la fórmula (10), fórmula E en donde p es un entero de 1 a 3; n es 1 ó 2; y RX es un alquilo inferior opcionalmente sustituido; siempre que los compuestos de fórmula (A-1) a (A-35) se excluyan, o un éster, un compuesto protegido en el amino en el anillo de la cadena de 7 lados, su sal o solvato farmacéuticamente aceptable.
ARP110101141A 2010-04-05 2011-04-05 Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas AR081758A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010087131 2010-04-05
JP2010274180 2010-12-09

Publications (1)

Publication Number Publication Date
AR081758A1 true AR081758A1 (es) 2012-10-17

Family

ID=44762902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101141A AR081758A1 (es) 2010-04-05 2011-04-05 Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas

Country Status (14)

Country Link
US (1) US9145425B2 (es)
EP (1) EP2557082A4 (es)
JP (1) JP5909441B2 (es)
KR (1) KR20130018845A (es)
CN (1) CN102918048A (es)
AR (1) AR081758A1 (es)
AU (1) AU2011236933A1 (es)
CA (1) CA2795322A1 (es)
IN (1) IN2012CN09242A (es)
MX (1) MX2012011521A (es)
RU (1) RU2012146986A (es)
TW (1) TW201139451A (es)
UY (1) UY33315A (es)
WO (1) WO2011125967A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049086A1 (en) 2007-10-09 2009-04-16 Larry Sutton Broad spectrum beta-lactamase inhibitors
KR101655961B1 (ko) * 2008-10-31 2016-09-08 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류
CN102918047A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
WO2011136268A1 (ja) * 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体
WO2012147773A1 (ja) 2011-04-28 2012-11-01 塩野義製薬株式会社 カテコールまたは擬似カテコール構造を有する新規セフェム化合物
CN103619853A (zh) 2011-06-27 2014-03-05 盐野义制药株式会社 具有吡啶鎓基的头孢烯化合物
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
JPWO2013051597A1 (ja) 2011-10-04 2015-03-30 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
CN104854113A (zh) 2012-10-29 2015-08-19 盐野义制药株式会社 2-烷基头孢烯化合物的中间体的生产方法
US9139743B2 (en) * 2013-01-31 2015-09-22 Xerox Corporation Malic acid derivatives as amorphous materials for phase change ink
JP6783497B2 (ja) * 2014-09-04 2020-11-11 塩野義製薬株式会社 セファロスポリン誘導体の中間体およびその製造方法
CA2959295C (en) * 2014-09-04 2023-08-22 Shionogi & Co., Ltd. A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
CN104817604B (zh) * 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
KR20180066264A (ko) * 2015-12-10 2018-06-18 나에자-알지엠 파마슈티칼스 유엘씨 세펨 화합물, 그의 제조 및 용도
WO2017199227A1 (en) 2016-05-20 2017-11-23 S & I Ophthalmic, Llc. Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
TW202024083A (zh) 2018-09-03 2020-07-01 德商拜耳廠股份有限公司 3,9-二氮雜螺[5.5]十一烷化合物
CA3119394A1 (en) * 2018-11-13 2020-05-22 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
WO2020206381A1 (en) * 2019-04-03 2020-10-08 Sutton Larry D Cephem compounds with latent reactive groups and methods of using and making same
AU2021210472A1 (en) * 2020-01-22 2022-07-21 Jiangsu Hengrui Medicine Co., Ltd. Cephalosporin antibacterial compound and pharmaceutical application thereof
CN115087633A (zh) 2020-02-11 2022-09-20 凯米诺瓦有限公司 由(r)-2-氨基丁酸合成s-氟丁酰草胺的方法
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
CN111714490B (zh) * 2020-07-20 2021-07-06 广东工业大学 一种化合物在制备抑制细菌群体感应系统药物中的应用
KR20230131292A (ko) * 2021-01-12 2023-09-12 상하이 센후이 메디슨 컴퍼니 리미티드 세팔로스포린 항균 화합물 및 이의 제조 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
AU2361184A (en) 1983-01-21 1984-07-26 Beecham Group Plc Disubstituted 6-penicillins and 7-cephalosporins
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
EP0203271B1 (en) 1985-03-01 1993-05-26 Takeda Chemical Industries, Ltd. Antibacterial compounds, their production and use
JPH068300B2 (ja) 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
EP0214600B1 (en) 1985-09-03 1992-12-02 Otsuka Kagaku Kabushiki Kaisha Cephalosporin derivatives
JPS62158291A (ja) 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
EP0241901B1 (en) 1986-04-14 1994-08-24 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
EP0346465B1 (en) 1986-04-14 1993-08-11 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vyniloxyiminoaminothiazole cephalosporing derivatives and process for their preparation
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
US5149803A (en) 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
US5244890A (en) * 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) * 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
US5143910A (en) * 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5126336A (en) 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5194433A (en) 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU1694099A (en) 1997-12-26 1999-07-19 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
US6713625B2 (en) 2002-05-23 2004-03-30 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of cefditoren using the thioester of thiazolylacetic acid
AU2003251627A1 (en) 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
JP3928086B2 (ja) 2005-03-29 2007-06-13 塩野義製薬株式会社 ３−プロペニルセフェム誘導体
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
SI2066659T1 (sl) 2006-09-29 2013-10-30 Grunenthal Gmbh Substituirani sulfonamidni derivati
DK2074120T3 (da) 2007-10-25 2010-06-14 Exelixis Inc Tropan-forbindelser
JP5713525B2 (ja) 2008-09-30 2015-05-07 三菱マテリアル株式会社 導電性インク組成物及び該組成物を用いた太陽電池セル及び太陽電池モジュールの製造方法
JP2010087130A (ja) 2008-09-30 2010-04-15 Toyota Motor Corp 半導体装置の製造方法
KR101655961B1 (ko) 2008-10-31 2016-09-08 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류
JP2010104035A (ja) 2010-01-25 2010-05-06 Toshiba Corp 受信装置及び受信方法
CN102918047A (zh) * 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
WO2011136268A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
TW201139451A (en) 2011-11-16
UY33315A (es) 2011-10-31
JPWO2011125967A1 (ja) 2013-07-11
RU2012146986A (ru) 2014-05-20
KR20130018845A (ko) 2013-02-25
US20130102583A1 (en) 2013-04-25
US9145425B2 (en) 2015-09-29
CN102918048A (zh) 2013-02-06
IN2012CN09242A (es) 2015-08-21
WO2011125967A1 (ja) 2011-10-13
JP5909441B2 (ja) 2016-04-26
AU2011236933A1 (en) 2013-05-02
EP2557082A4 (en) 2013-08-28
MX2012011521A (es) 2013-03-08
CA2795322A1 (en) 2011-10-13
EP2557082A1 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
AR081758A1 (es) Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas
AR081757A1 (es) Compuestos cefem que contienen seudocatecol
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
EA201171328A1 (ru) Производное замещенного изохинолина
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR085327A1 (es) Inhibidores del virus de la hepatitis c
EA201591000A1 (ru) Пирролобензодиазепины
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR065354A1 (es) Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4.
AR085852A1 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina y composiciones farmaceuticas que los contienen
RS54708B1 (en) ARYLETINYL DERIVATIVES
AR085039A1 (es) DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
RS54288B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
ECSP10010380A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
AR076880A1 (es) Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure